Cancer Genetics and Epigenetics, 2025, Vol.13, No.1, 21-31 http://medscipublisher.com/index.php/cge 29 Ceder Y., Bjartell A., Culig Z., Rubin M., Tomlins S., and Visakorpi T., 2016, The molecular evolution of castration-resistant prostate cancer, European Urology Focus, 2(5): 506-513. https://doi.org/10.1016/j.euf.2016.11.012 Chen J., Wang F., Xu H., Xu L., Chen D., Wang J., Huang S., Wen Y., and Fang L., 2020, Long non-coding RNA SNHG1 Regulates the Wnt/β-Catenin and PI3K/AKT/mTOR signaling pathways via EZH2 to affect the proliferation, apoptosis, and autophagy of prostate cancer cell, Frontiers in Oncology, 10: 552907. https://doi.org/10.3389/fonc.2020.552907 Cheng B.S., and Huang H., 2023, Expanding horizons in overcoming therapeutic resistance in castration-resistant prostate cancer: targeting the androgen receptor-regulated tumor immune microenvironment, Cancer Biology and Medicine, 20(8): 568-574. https://doi.org/10.20892/j.issn.2095-3941.2023.0256 Chung C., and Abboud K., 2022, Targeting the androgen receptor signaling pathway in advanced prostate cancer, American Journal of Health-System Pharmacy, 79(15): 1224-1235. https://doi.org/10.1093/ajhp/zxac105 Ciccarese C., Massari F., Iacovelli R., Fiorentino M., Montironi R., Di Nunno V., Giunchi F., Brunelli M., and Tortora G., 2017, Prostate cancer heterogeneity: discovering novel molecular targets for therapy, Cancer Treatment Reviews, 54: 68-73. https://doi.org/10.1016/j.ctrv.2017.02.001 Corn P., 2012, The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development, Cancer Management and Research, 4: 183-193. https://doi.org/10.2147/CMAR.S32839 Dai Q., Peng Y., He P., and Wu X., 2024, Interactions and communications in the prostate tumour microenvironment: evolving towards effective cancer therapy, Journal of Drug Targeting, 33(3): 295-315. https://doi.org/10.1080/1061186X.2024.2418344 Deluce J., Cardenas L., Lalani A., Vareki M., and Fernandes R., 2022, Emerging biomarker-guided therapies in prostate cancer, Current Oncology, 29: 5054-5076. https://doi.org/10.3390/curroncol29070400 Dobosy J., Roberts J., Fu V., and Jarrard D., 2007, The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia, The Journal of Urology, 177(3): 822-831. https://doi.org/10.1016/J.JURO.2006.10.063 Gao N., Zhang Z., Jiang B., and Shi X., 2003, Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer, Biochemical and Biophysical Research Communications, 310(4): 1124-1132. https://doi.org/10.1016/J.BBRC.2003.09.132 Giunta E., Annaratone L., Bollito E., Porpiglia F., Cereda M., Banna G., Mosca A., Marchiò C., and Rescigno P., 2021, Molecular characterization of prostate cancers in the precision medicine era, Cancers, 13(19): 4771. https://doi.org/10.3390/cancers13194771 Gonzalgo M., and Isaacs W., 2003, Molecular pathways to prostate cancer, The Journal of Urology, 170(6): 2444-2252. https://doi.org/10.1097/01.JU.0000085381.20139.B6 Grypari I.M., Tzelepi V., and Gyftopoulos K., 2023, DNA damage repair pathways in prostate cancer: a narrative review of molecular mechanisms, emerging biomarkers and therapeutic targets in precision oncology, International Journal of Molecular Sciences, 24(14): 11418. https://doi.org/10.3390/ijms241411418. Hua H., Zhang H., Chen J., Wang J., Liu J., and Jiang Y., 2021, Targeting akt in cancer for precision therapy, Journal of Hematology and Oncology, 14(1): 128. https://doi.org/10.1186/s13045-021-01137-8 Jacob A., Raj R., Allison D., and Myint Z., 2021, Androgen receptor signaling in prostate cancer and therapeutic strategies, Cancers, 13(21): 5417. https://doi.org/10.3390/cancers13215417 Jamroze A., Chatta G., and Tang D.G., 2021, Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance, Cancer Letters, 518: 1-9. https://doi.org/10.1016/j.canlet.2021.06.006 Kim S., and Cho S., 2022, The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment, Frontiers in Pharmacology, 13: 868695. https://doi.org/10.3389/fphar.2022.868695 Koivisto P., Kononen J., Palmberg C., Tammela T., Hyytinen E., Isola J., Trapman J., Cleutjens K., Noordzij A., Visakorpi T., and Kallioniemi O., 1997, Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer, Cancer Research, 57(2): 314-319. Koochekpour S., 2010, Androgen receptor signaling and mutations in prostate cancer, Asian Journal of Andrology, 12(5): 639-57. https://doi.org/10.1038/aja.2010.89 Koushyar S., Meniel V., Phesse T., and Pearson H., 2022, Exploring the wnt pathway as a therapeutic target for prostate cancer, Biomolecules, 12(2): 309. https://doi.org/10.3390/biom12020309 Ku S., Gleav M., and Beltran H., 2019, Towards precision oncology in advanced prostate cancer, Nature Reviews Urology, 16: 645-654. https://doi.org/10.1038/s41585-019-0237-8
RkJQdWJsaXNoZXIy MjQ4ODYzNA==